Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Vote in favor of your Number one Kind of Gems - 2Party Urban areas of the World
- 3Kiev declares energy emergency after Russian attacks amid winter cold
- 4Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 56 Web-based Course Stages for Successful Learning and Educating
- The Response Uncovered: Disentangling the Secrets of the Universe
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- The Main 15 Applications for Efficiency and Association
- Where America’s CO2 emissions come from – what you need to know, in charts
- The most effective method to Pick the Best Material Organization: Insider Tips
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
